ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors
November 17 2021 - 7:00AM
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an
end-to-end commercial biopharmaceutical company dedicated to
manufacturing, marketing and developing specialty plasma-derived
biologics, today announced that Cyndi Tolman, ADMA’s Senior Vice
President of Plasma Services, has been elected to serve on the PPTA
Source Board of Directors (“PPTA Source Board”) for the 2022 to
2024 election term.
“Mrs. Tolman’s appointment to the PPTA Source Board of Directors
is a well-deserved testament to her leadership capabilities and
accomplishments as a part of the rapid and successful expansion of
the ADMA BioCenters collection network,” said Adam Grossman,
President and Chief Executive Officer of ADMA. “ADMA welcomes the
opportunity to have a voice on the PPTA Source Board and we are
confident in Cyndi’s ability and decades-long experience, that will
allow her to provide valuable input to further the industry’s
mission to advocate for access of plasma-derived therapies for
patients in need.”
“I am honored to have been elected by my peers to this esteemed
board and look forward to bringing ideas and recommendations based
upon my over 20 years of plasma collections experience to the
PPTA,” said Cynthia Tolman, Senior Vice President, Plasma Services
of ADMA BioCenters. “Our recent expansion of ADMA’s collection
center network, including the implementation of the latest
technology in collection methods, coupled with our regulatory and
quality experience, will allow for additional insights into ways we
can enhance the donor experience and ensure the safety of our
valuable and generous plasma donors who give the gift of saving
lives with every donation they make.”
The Plasma Protein Therapeutics Association (PPTA) represents
the private sector manufacturers of plasma-derived and recombinant
analog therapies, collectively known as plasma protein therapies
and the collectors of source plasma used for fractionation. These
therapies are used by small patient populations worldwide to treat
a variety of rare diseases and serious medical
conditions. PPTA works globally to advocate for access to and
affordability of therapies for patients, engage in constructive
dialogue with regulatory agencies, and collaborate with patient
advocacy organizations. Mrs. Tolman is one of five new
appointments to the PPTA Source Board, which consists of global
representatives from the plasma industry as to ensure balanced
representation.
About ADMA BioCenters
ADMA BioCenters operates U.S. Food and Drug
Administration (FDA)-licensed facilities specializing in the
collection of human plasma used to make special medications for the
treatment and prevention of certain infectious diseases. Managed by
a team of experts who have decades of experience in the specialized
field of plasma collection, ADMA BioCenters provides a safe,
professional and pleasant donation environment. ADMA BioCenters
strictly follows FDA regulations and guidance and enforces current
good manufacturing practices (cGMP) in all of its facilities. For
more information about ADMA BioCenters, please visit
www.admabiocenters.com.
About ADMA Biologics, Inc.
(ADMA)
ADMA Biologics is an end-to-end commercial
biopharmaceutical company dedicated to manufacturing, marketing and
developing specialty plasma-derived biologics for the treatment of
immunodeficient patients at risk for infection and others at risk
for certain infectious diseases. ADMA currently manufactures and
markets three FDA-approved plasma-derived biologics for the
treatment of immune deficiencies and the prevention of certain
infectious diseases: BIVIGAM® (immune globulin intravenous, human)
for the treatment of primary humoral immunodeficiency (PI);
ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for
the treatment of PI; and NABI-HB® (hepatitis B immune globulin,
human) to provide enhanced immunity against the hepatitis B virus.
ADMA manufactures its immune globulin products at its FDA-licensed
plasma fractionation and purification facility located in Boca
Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also
operates as an FDA-licensed source plasma collector in the U.S.,
which provides a portion of its blood plasma for the manufacture of
its products. ADMA’s mission is to manufacture, market and develop
specialty plasma-derived, human immune globulins targeted to niche
patient populations for the treatment and prevention of certain
infectious diseases and management of immune compromised patient
populations who suffer from an underlying immune deficiency, or who
may be immune compromised for other medical reasons. ADMA has
received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793
and 10,259,865 related to certain aspects of its products and
product candidates. For more information, please visit
www.admabiologics.com.
COMPANY
CONTACT: Skyler BloomDirector,
Investor Relations and Corporate Strategy | 201-478-5552 |
sbloom@admabio.com
INVESTOR RELATIONS CONTACT:Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 |
michelle@argotpartners.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Apr 2023 to Apr 2024